Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT04239391

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04239391
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04239391. Randomized; no masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2023-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Condition
End Stage Renal Disease
Intervention (Drug)
Triferic
Lead sponsor
Rockwell Medical Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04239391
Content hash
e343c15506ef6ec76a0d6248e84d480da4a40514c0197256d7e711ffc3fa8382